Takeda and Global Plasma Leaders Collaborate on the Development of a COVID-19 Hyperimmune Therapy

In the fight against the COVID-19 pandemic, pharmaceutical company Takeda has formed an alliance with Biotest, BPL, LFB, and Octapharma to develop a potential plasma-derived therapy for treating COVID-19.

“Unprecedented times call for bold moves,” said Julie Kim, Takeda’s President of Plasma-Derived Therapies Business Unit. “We collectively agree that by collaborating and bringing industry resources together, we could accelerate bringing a potential therapy to market as well as increase the potential supply. We invite companies and institutions focusing on plasma to support or join our alliance.”

Like Takeda, many of our members continue to go beyond the ordinary to fight the spread of the infection and its deadly consequences.

But what comes next? Now, as the COVID-19 lockdown measures are slowly starting to ease, there is an urgency for togetherness: for enterprises, industry federations, policymakers, and civil society organisations to collaborate and build back better. How? By incubating collaborations to develop practical and scalable solutions. How? Engage in  the European Pact for Sustainable Industry.

---